Literature DB >> 7577203

Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpatient resource utilization.

D A Freund1, R S Dittus.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577203

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


× No keyword cloud information.
  3 in total

1.  The problem of protocol driven costs in pharmacoeconomic analysis.

Authors:  D Coyle; K M Lee
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 2.  Pharmacoeconomic considerations in treating patients with acute leukaemia.

Authors:  V Jønsson; M M Hansen; P Ljungman; S Kaasa
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

Review 3.  Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.

Authors:  Ronit Gurion; Yulia Belnik-Plitman; Anat Gafter-Gvili; Mical Paul; Liat Vidal; Isaac Ben-Bassat; Ofer Shpilberg; Pia Raanani
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.